Details of the Drug

General Information of Drug (ID: DMPN1TW)

Drug Name

Dofetilide

Synonyms

Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE

Indication

Disease Entry	ICD 11	Status	REF
Sinus rhythm disorder	BC9Y	Approved	[1], [2]

Therapeutic Class

Antiarrhythmic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

441.6

Topological Polar Surface Area (xlogp)

1.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The absorption of drug is more than 90% [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability: 96% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 5.2 mL/min/kg [6]
Elimination: 64% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 hours [6]
Metabolism: The drug is metabolized via the hepatic [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03774 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.36% [6]
Vd: The volume of distribution (Vd) of drug is 3 L/kg [8]

Chemical Identifiers

Formula: C19H27N3O5S2
IUPAC Name: N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
Canonical SMILES: CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
InChI: InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
InChIKey: IXTMWRCNAAVVAI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71329
ChEBI ID: CHEBI:4681
CAS Number: 115256-11-6
DrugBank ID: DB00204
TTD ID: D0NW3X
VARIDT ID: DR00724
INTEDE ID: DR0522
ACDINA ID: D00208

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug and toxin extrusion protein 2 (SLC47A2)	DT3TX4H	S47A2_HUMAN	Substrate	[10]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[10]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dofetilide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Sotalol.	Cardiac arrhythmia [BC9Z]	[40]
Moricizine	DMOMBJW	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Moricizine.	Cardiac arrhythmia [BC9Z]	[40]
-----------

Coadministration of a Drug Treating the Disease Different from Dofetilide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[41]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Midostaurin.	Acute myeloid leukaemia [2A60]	[41]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Idarubicin.	Acute myeloid leukaemia [2A60]	[41]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[41]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Arn-509.	Acute myeloid leukaemia [2A60]	[41]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[41]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Oliceridine.	Acute pain [MG31]	[41]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[41]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Tacrine.	Alzheimer disease [8A20]	[41]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Galantamine.	Alzheimer disease [8A20]	[41]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Rivastigmine.	Alzheimer disease [8A20]	[41]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Dofetilide and Metronidazole.	Amoebiasis [1A36]	[42]
Ranolazine	DM0C9IL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ranolazine.	Angina pectoris [BA40]	[41]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Ivabradine.	Angina pectoris [BA40]	[43]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Bepridil.	Angina pectoris [BA40]	[41]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Dronedarone.	Angina pectoris [BA40]	[41]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Dofetilide caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[40]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[41]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[41]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Promazine.	Appearance/behaviour symptom [MB23]	[41]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Cilostazol.	Arterial occlusive disease [BD40]	[41]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Voriconazole.	Aspergillosis [1F20]	[41]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Posaconazole.	Aspergillosis [1F20]	[41]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Levalbuterol.	Asthma [CA23]	[44]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Terbutaline.	Asthma [CA23]	[45]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Dofetilide caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[40]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Pirbuterol.	Asthma [CA23]	[45]
Isoetharine	DMITSEH	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Isoetharine.	Asthma [CA23]	[45]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Salbutamol.	Asthma [CA23]	[46]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Formoterol.	Asthma [CA23]	[45]
Atomoxetine	DM5L6HI	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[41]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[41]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[41]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[41]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Dofetilide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[41]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Dofetilide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[41]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[47]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Dofetilide caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Capreomycin	DMNZBRY	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Capreomycin.	Bacterial infection [1A00-1C4Z]	[40]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Moxifloxacin	DMU8V4S	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Dofetilide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[48]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Retigabine.	Behcet disease [4A62]	[41]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Loperamide.	Bowel habit change [ME05]	[49]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Eribulin.	Breast cancer [2C60-2C6Y]	[41]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lapatinib.	Breast cancer [2C60-2C6Y]	[41]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Dofetilide caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Dofetilide caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[41]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Toremifene.	Breast cancer [2C60-2C6Y]	[41]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Bosutinib.	Breast cancer [2C60-2C6Y]	[41]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Grepafloxacin.	Bronchitis [CA20]	[47]
Iodipamide	DMXIQYS	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Iodipamide.	Cholelithiasis [DC11]	[50]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Dofetilide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[41]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[45]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[45]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[45]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[45]
Phenylbutazone	DMAYL0T	Minor	Increased metabolism of Dofetilide caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[40]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Oxaliplatin.	Colorectal cancer [2B91]	[41]
Panitumumab	DMQPD1F	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Panitumumab.	Colorectal cancer [2B91]	[40]
Isoproterenol	DMK7MEY	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Isoproterenol.	Conduction disorder [BC63]	[45]
Bupivacaine	DM4PRFC	Moderate	Increased risk of bradycardia by the combination of Dofetilide and Bupivacaine.	Corneal disease [9A76-9A78]	[51]
Levobupivacaine	DM783CH	Moderate	Increased risk of bradycardia by the combination of Dofetilide and Levobupivacaine.	Corneal disease [9A76-9A78]	[51]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Halothane.	Corneal disease [9A76-9A78]	[41]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Propofol.	Corneal disease [9A76-9A78]	[52]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Sevoflurane.	Corneal disease [9A76-9A78]	[41]
Lidocaine	DML4ZOT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lidocaine.	Corneal disease [9A76-9A78]	[40]
Ropivacaine	DMSPJG2	Moderate	Increased risk of atrioventricular block by the combination of Dofetilide and Ropivacaine.	Corneal disease [9A76-9A78]	[51]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Probucol.	Coronary atherosclerosis [BA80]	[41]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Methadone.	Cough [MD12]	[41]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Clofazimine.	Crohn disease [DD70]	[41]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Mifepristone.	Cushing syndrome [5A70]	[41]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Pasireotide.	Cushing syndrome [5A70]	[41]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Osilodrostat.	Cushing syndrome [5A70]	[41]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Dofetilide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[40]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Dofetilide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[40]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Dofetilide caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[53]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Sertraline.	Depression [6A70-6A7Z]	[41]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Trimipramine.	Depression [6A70-6A7Z]	[41]
Imipramine	DM2NUH3	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Imipramine.	Depression [6A70-6A7Z]	[41]
Fluoxetine	DM3PD2C	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Fluoxetine.	Depression [6A70-6A7Z]	[41]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Nortriptyline.	Depression [6A70-6A7Z]	[41]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Dofetilide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[40]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Escitalopram.	Depression [6A70-6A7Z]	[41]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Clomipramine.	Depression [6A70-6A7Z]	[41]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Trazodone.	Depression [6A70-6A7Z]	[41]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Amoxapine.	Depression [6A70-6A7Z]	[41]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Mirtazapine.	Depression [6A70-6A7Z]	[41]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Protriptyline.	Depression [6A70-6A7Z]	[41]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Doxepin.	Depression [6A70-6A7Z]	[41]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Maprotiline.	Depression [6A70-6A7Z]	[41]
Venlafaxine	DMR6QH0	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Venlafaxine.	Depression [6A70-6A7Z]	[41]
Citalopram derivative 1	DMITX1G	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Citalopram derivative 1.	Discovery agent [N.A.]	[41]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[41]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Deutetrabenazine.	Dystonic disorder [8A02]	[41]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ingrezza.	Dystonic disorder [8A02]	[41]
Primidone	DM0WX6I	Minor	Increased metabolism of Dofetilide caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Oxcarbazepine	DM5PU6O	Minor	Increased metabolism of Dofetilide caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Dofetilide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Phenytoin	DMNOKBV	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Phenytoin.	Epilepsy/seizure [8A61-8A6Z]	[40]
Fosphenytoin	DMOX3LB	Minor	Increased metabolism of Dofetilide caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Dofetilide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Carbamazepine	DMZOLBI	Minor	Increased metabolism of Dofetilide caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Diphenhydramine	DMKQTBA	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[42]
Ethacrynic acid	DM60QMR	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Ethacrynic acid.	Essential hypertension [BA00]	[40]
Bendroflumethiazide	DM7EVLC	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Bendroflumethiazide.	Essential hypertension [BA00]	[40]
Benzthiazide	DMQWZ0H	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Benzthiazide.	Essential hypertension [BA00]	[40]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Solifenacin.	Functional bladder disorder [GC50]	[41]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Dofetilide caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[41]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Pentamidine.	Fungal infection [1F29-1F2F]	[41]
Clotrimazole	DMMFCIH	Moderate	Decreased metabolism of Dofetilide caused by Clotrimazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[40]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Dofetilide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[42]
Amphotericin B	DMTAJQE	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Amphotericin B.	Fungal infection [1F29-1F2F]	[40]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[41]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[41]
Acetazolamide	DM1AF5U	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Acetazolamide.	Glaucoma [9C61]	[40]
Methazolamide	DM7J2TA	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Methazolamide.	Glaucoma [9C61]	[40]
Dichlorphenamide	DMH7IDQ	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Dichlorphenamide.	Glaucoma [9C61]	[40]
Sulfinpyrazone	DMEV954	Minor	Increased metabolism of Dofetilide caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[40]
Triamterene	DM2HU9I	Moderate	Decreased elimination of Dofetilide caused by Triamterene mediated competitive inhibition of renal tubular secretion.	Heart failure [BD10-BD1Z]	[40]
Chlorothiazide	DMLHESP	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Chlorothiazide.	Heart failure [BD10-BD1Z]	[40]
Furosemide	DMMQ8ZG	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Furosemide.	Heart failure [BD10-BD1Z]	[40]
Amiloride	DMRTSGP	Moderate	Decreased elimination of Dofetilide caused by Amiloride mediated competitive inhibition of renal tubular secretion.	Heart failure [BD10-BD1Z]	[40]
Bumetanide	DMRV7H0	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Bumetanide.	Heart failure [BD10-BD1Z]	[40]
Hydroflumethiazide	DMVPUQI	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[40]
Torasemide	DMXKJ6C	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Torasemide.	Heart failure [BD10-BD1Z]	[40]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Dofetilide caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[40]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Dofetilide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[40]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Dofetilide caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[40]
Rifampin	DMA8J1G	Minor	Increased metabolism of Dofetilide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[54]
Rifapentine	DMCHV4I	Minor	Increased metabolism of Dofetilide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[40]
Indinavir	DM0T3YH	Moderate	Decreased metabolism of Dofetilide caused by Indinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Dofetilide caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Dofetilide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Dofetilide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Dolutegravir	DMCZGRE	Major	Decreased clearance of Dofetilide due to the transporter inhibition by Dolutegravir.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Dofetilide caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Dofetilide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Dofetilide caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Dofetilide caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Dofetilide caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[40]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Dofetilide caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[40]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Dofetilide caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[40]
Amlodipine	DMBDAZV	Moderate	Decreased metabolism of Dofetilide caused by Amlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[40]
Fenoldopam	DMFAOKP	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Fenoldopam.	Hypertension [BA00-BA04]	[40]
Indapamide	DMGN1PW	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Indapamide.	Hypertension [BA00-BA04]	[40]
Trichlormethiazide	DMHAQCO	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Trichlormethiazide.	Hypertension [BA00-BA04]	[40]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Dofetilide caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[57]
Fludrocortisone	DMUDIR8	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Dofetilide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[40]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Dofetilide caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[40]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[58]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[41]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Crizotinib.	Lung cancer [2C25]	[41]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Dofetilide caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[59]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ceritinib.	Lung cancer [2C25]	[41]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Dofetilide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[60]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Osimertinib.	Lung cancer [2C25]	[41]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Selpercatinib.	Lung cancer [2C25]	[41]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lumefantrine.	Malaria [1F40-1F45]	[42]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Halofantrine.	Malaria [1F40-1F45]	[61]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Chloroquine.	Malaria [1F40-1F45]	[41]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Quinine.	Malaria [1F40-1F45]	[41]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Primaquine.	Malaria [1F40-1F45]	[41]
Mefloquine	DMWT905	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Mefloquine.	Malaria [1F40-1F45]	[41]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[41]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Dofetilide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[62]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Vemurafenib.	Melanoma [2C30]	[41]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Dofetilide and LGX818.	Melanoma [2C30]	[41]
Danazol	DML8KTN	Moderate	Decreased metabolism of Dofetilide caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[40]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Dofetilide caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[63]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Panobinostat.	Multiple myeloma [2A83]	[41]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Thalidomide.	Multiple myeloma [2A83]	[42]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Siponimod.	Multiple sclerosis [8A40]	[42]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Ozanimod.	Multiple sclerosis [8A40]	[64]
Rifabutin	DM1YBHK	Minor	Increased metabolism of Dofetilide caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[40]
Bexarotene	DMOBIKY	Minor	Increased metabolism of Dofetilide caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[40]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Romidepsin.	Mycosis fungoides [2B01]	[41]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Dofetilide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[40]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[41]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Dofetilide caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[40]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[41]
Modafinil	DMYILBE	Minor	Increased metabolism of Dofetilide caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[65]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Droperidol.	Nausea/vomiting [MD90]	[41]
Dimenhydrinate	DM264B3	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Dimenhydrinate.	Nausea/vomiting [MD90]	[42]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Promethazine.	Nausea/vomiting [MD90]	[41]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Palonosetron.	Nausea/vomiting [MD90]	[41]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Granisetron.	Nausea/vomiting [MD90]	[41]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Dolasetron.	Nausea/vomiting [MD90]	[41]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ondansetron.	Nausea/vomiting [MD90]	[41]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Entrectinib.	Non-small cell lung cancer [2C25]	[41]
Chlorthalidone	DM4DMBT	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Chlorthalidone.	Oedema [MG29]	[40]
Metolazone	DMB39LO	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Metolazone.	Oedema [MG29]	[40]
Polythiazide	DMCH80F	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Polythiazide.	Oedema [MG29]	[40]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[43]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lofexidine.	Opioid use disorder [6C43]	[41]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Rucaparib.	Ovarian cancer [2C73]	[41]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[41]
Prilocaine	DMI7DZ2	Moderate	Increased risk of bradycardia by the combination of Dofetilide and Prilocaine.	Pain [MG30-MG3Z]	[51]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Buprenorphine.	Pain [MG30-MG3Z]	[41]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Triclabendazole.	Parasitic worm infestation [1F90]	[41]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Pimavanserin.	Parkinsonism [8A00]	[41]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Apomorphine.	Parkinsonism [8A00]	[41]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dofetilide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[66]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Famotidine.	Peptic ulcer [DA61]	[42]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Dofetilide caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[40]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[67]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lefamulin.	Pneumonia [CA40]	[68]
Hydrocortisone	DMGEMB7	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[40]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ritodrine.	Preterm labour/delivery [JB00]	[45]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Degarelix.	Prostate cancer [2C82]	[41]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Dofetilide and ABIRATERONE.	Prostate cancer [2C82]	[41]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Nilutamide.	Prostate cancer [2C82]	[41]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Enzalutamide.	Prostate cancer [2C82]	[41]
Flutamide	DMK0O7U	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Flutamide.	Prostate cancer [2C82]	[41]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Relugolix.	Prostate cancer [2C82]	[41]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Bicalutamide.	Prostate cancer [2C82]	[41]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Alfuzosin.	Prostate hyperplasia [GA90]	[41]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[41]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[41]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Dofetilide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[69]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Sorafenib.	Renal cell carcinoma [2C90]	[41]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[41]
Dexamethasone	DMMWZET	Minor	Increased metabolism of Dofetilide caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[40]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Quetiapine.	Schizophrenia [6A20]	[41]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Mesoridazine.	Schizophrenia [6A20]	[41]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Thioridazine.	Schizophrenia [6A20]	[41]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Aripiprazole.	Schizophrenia [6A20]	[42]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Iloperidone.	Schizophrenia [6A20]	[41]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Paliperidone.	Schizophrenia [6A20]	[41]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Haloperidol.	Schizophrenia [6A20]	[41]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Perphenazine.	Schizophrenia [6A20]	[41]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Chlorpromazine.	Schizophrenia [6A20]	[41]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Clozapine.	Schizophrenia [6A20]	[41]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Trifluoperazine.	Schizophrenia [6A20]	[41]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ziprasidone.	Schizophrenia [6A20]	[41]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Risperidone.	Schizophrenia [6A20]	[41]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Dofetilide and Olanzapine.	Schizophrenia [6A20]	[42]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Asenapine.	Schizophrenia [6A20]	[41]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Pimozide.	Schizophrenia [6A20]	[43]
Mepivacaine	DMH2NMY	Moderate	Increased risk of atrioventricular block by the combination of Dofetilide and Mepivacaine.	Sensation disturbance [MB40]	[51]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[70]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Dofetilide caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[40]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Dofetilide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
Armodafinil	DMGB035	Minor	Increased metabolism of Dofetilide caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[65]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Dofetilide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[41]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[41]
Prednisolone	DMQ8FR2	Minor	Increased metabolism of Dofetilide caused by Prednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
Cisplatin	DMRHGI9	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[40]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[41]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[41]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[41]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Pitolisant.	Somnolence [MG42]	[41]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[41]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[40]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Dofetilide and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[71]
Zithromax	DMN4H2O	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Zithromax.	Syphilis [1A61-1A6Z]	[41]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Dofetilide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[72]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Anagrelide.	Thrombocytosis [3B63]	[41]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Dofetilide caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[40]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Lenvatinib.	Thyroid cancer [2D10]	[41]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Cabozantinib.	Thyroid cancer [2D10]	[41]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Papaverine.	Tonus and reflex abnormality [MB47]	[73]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Tizanidine.	Tonus and reflex abnormality [MB47]	[41]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Dofetilide and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[69]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Tacrolimus.	Transplant rejection [NE84]	[41]
Metformin	DM89QE1	Moderate	Decreased elimination of Dofetilide caused by Metformin mediated competitive inhibition of renal tubular secretion.	Type 2 diabetes mellitus [5A11]	[40]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[41]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[41]
Bretylium	DM1FX74	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Bretylium.	Ventricular tachyarrhythmia [BC71]	[40]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[40]
Mexiletine	DMCTE9R	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Mexiletine.	Ventricular tachyarrhythmia [BC71]	[40]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[40]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[40]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[40]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[40]
Tocainide	DMYNMDP	Major	Increased risk of prolong QT interval by the combination of Dofetilide and Tocainide.	Ventricular tachyarrhythmia [BC71]	[40]
-----------


⏷ Show the Full List of 291 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dofetilide 0.125 mg capsule	0.125 mg	Oral Capsule	Oral
Dofetilide 0.25 mg capsule	0.25 mg	Oral Capsule	Oral
Dofetilide 0.5 mg capsule	0.5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2604).
2	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10	FDA Drug Development and Drug Interactions
11	Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
22	Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
23	Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
24	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
25	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
26	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
27	The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
28	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
29	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
30	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
31	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
32	Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
33	Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
34	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
35	Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
36	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
37	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
38	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
39	Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
40	Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
41	Canadian Pharmacists Association.
42	Cerner Multum, Inc. "Australian Product Information.".
43	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
45	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
46	Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
47	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
48	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
49	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
50	Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
51	Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
52	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
53	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
54	Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
55	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
56	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
57	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
58	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
59	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
61	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
62	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
63	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
64	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
65	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
66	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
67	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
68	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
69	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
70	Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
71	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
72	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
73	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]